Abstract
Immunopharmacology has changed dramatically over the past 25 years. Although a variety of traditional nonspecific immunosuppressive drug therapies are available for the treatment of autoimmune disease and organ transplantation rejection, with advances in cell biology and monoclonal antibody technology, a highly specific antibody can be engineered to cell surface determinants on immune cells or tumors or to neutralize inflammatory and immune mediators from an immune response. Many of these modalities are still in early phases of study for the treatment of autoimmune disease. In addition to therapies that suppress immune responses, advances in molecular biology have led to new agents and methods to enhance immune responses and correct immune deficits, such as growth factor replacement and cytokine therapies. Finally, gene therapy is a method for the long-term treatment of disorders in which a defective gene leads to disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2008-2017 |
| Number of pages | 10 |
| Journal | Journal of the American Medical Association |
| Volume | 278 |
| Issue number | 22 |
| State | Published - Dec 10 1997 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Immunopharmacology : Immunomodulation and immunotherapy. / Ballow, Mark; Nelson, Robert.
In: Journal of the American Medical Association, Vol. 278, No. 22, 10.12.1997, p. 2008-2017.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Immunopharmacology
T2 - Immunomodulation and immunotherapy
AU - Ballow, Mark
AU - Nelson, Robert
PY - 1997/12/10
Y1 - 1997/12/10
N2 - Immunopharmacology has changed dramatically over the past 25 years. Although a variety of traditional nonspecific immunosuppressive drug therapies are available for the treatment of autoimmune disease and organ transplantation rejection, with advances in cell biology and monoclonal antibody technology, a highly specific antibody can be engineered to cell surface determinants on immune cells or tumors or to neutralize inflammatory and immune mediators from an immune response. Many of these modalities are still in early phases of study for the treatment of autoimmune disease. In addition to therapies that suppress immune responses, advances in molecular biology have led to new agents and methods to enhance immune responses and correct immune deficits, such as growth factor replacement and cytokine therapies. Finally, gene therapy is a method for the long-term treatment of disorders in which a defective gene leads to disease.
AB - Immunopharmacology has changed dramatically over the past 25 years. Although a variety of traditional nonspecific immunosuppressive drug therapies are available for the treatment of autoimmune disease and organ transplantation rejection, with advances in cell biology and monoclonal antibody technology, a highly specific antibody can be engineered to cell surface determinants on immune cells or tumors or to neutralize inflammatory and immune mediators from an immune response. Many of these modalities are still in early phases of study for the treatment of autoimmune disease. In addition to therapies that suppress immune responses, advances in molecular biology have led to new agents and methods to enhance immune responses and correct immune deficits, such as growth factor replacement and cytokine therapies. Finally, gene therapy is a method for the long-term treatment of disorders in which a defective gene leads to disease.
UR - http://www.scopus.com/inward/record.url?scp=0031469099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031469099&partnerID=8YFLogxK
M3 - Review article
C2 - 9396664
AN - SCOPUS:0031469099
VL - 278
SP - 2008
EP - 2017
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
SN - 0002-9955
IS - 22
ER -